IgA Nephropathy Complicated with X-linked Thrombocytopenia by Kakio, Yuki et al.
I gA nephropathy is the most common glomerulo-nephritis in Japan.  Renal biopsy is essential to 
diagnose this disease.  Upon diagnosis,  patients with 
IgA nephropathy are immediately treated with an 
appropriate remission induction therapy to prevent 
chronic renal failure.  Among the several ideal treat-
ment strategies for IgA nephropathy,  a tonsillectomy 
plus steroid pulse therapy has successfully achieved 
complete remission without any fatal or other adverse 
effects [1-3].
Wiskott-Aldrich syndrome (WAS) is defined as an 
inherited blood cell disorder due to mutations in the 
X-chromosome gene WASP (Wiskott-Aldrich syn-
drome protein),  which was characterized originally by 
thrombocytopenia,  immunodeficiency and eczema [4].  
WASP consists of 12 exons containing 1823 base pairs.  
It encodes a 502-amino acid protein that is expressed 
selectively in hematopoietic stem cell-derived lineages 
[5-8].  WASP gene mutations result in three distinct 
clinical phenotypes: classic WAS,  X-linked thrombo-
cytopenia (XLT),  and X-linked neutropenia (XLN) 
[9 , 10].  Mutations that completely avert WASP expres-
sion typically lead to the classic phenotype.  Missense 
mutations resulting in the expression of defective WASP,  
often in a reduced quantity of mature protein,  most 
often result in the XLT phenotype,  sometimes with only 
intermittent thrombocytopenia [11].  XLN is caused by 
gain-of-function mutations that result in constitutively 
activated WASP [12-14].
Renal involvement has been occasionally observed in 
WAS and XLT [15 , 16].  So far,  the pathogenesis of 
WAS/XLT-associated nephropathy remains unclear,  
because the tendency of patients with WAS/XLT-
associated nephropathy to bleed renders renal histopa-
thology difficult.  Here we describe a case of a patient 
with XLT who was diagnosed with IgA nephropathy 
(IgAN) by renal biopsy and then successfully treated 
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Renal involvement is occasionally observed in Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytope-
nia (XLT).  It has been reported that galactose-deficient IgA is a closely linked to IgA nephropathy (IgAN),  sug-
gesting that patients with XLT/WAS associated with reduced galactosylation on serum IgA are susceptible to 
IgAN.  It is necessary to pay more attention to patients with IgAN due to the potential complication with XLT/
WAS.  We here present a patient of XLT complicated with mild IgAN who underwent tonsillectomy combined 
with steroid pulse therapy to achieve complete clinical remission.
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with tonsillectomy combined with steroid pulse therapy.
Case Presentation
The patient was a 16-year-old man.  At the age of 3 
months,  he developed systemic and oral purpura and 
was referred at that time to a hospital,  where laboratory 
data revealed that he had thrombocytopenia 
(26,000/mm3),  but no abnormality was observed in a 
bone marrow biopsy.  Further,  he had neither 
anti-platelet antibody nor virus infection.  Given these 
observations,  he was suspected of having Wiskott−
Aldrich syndrome (WAS).  A genetic investigation 
demonstrated that he had a WASP gene mutation 
(details of the mutation are unavailable).  However,  he 
did not show any immune disorder.  Finally,  he was 
diagnosed with X-linked thrombocytopenia (XLT),  a 
mild case of WAS.  After that,  he showed no symptoms 
and his doctor took a wait-and-see approach on an out-
patient basis.  His platelet count was kept to about 
70,000~90,000/mm3.
Fifteen years later,  he presented with hematuria at a 
routine school health check.  Further,  he developed 
proteinuria (0.45 g/gCr) a year after that,  and then was 
referred to our hospital for a renal biopsy.
He had anamnestic history of macrohematuria after 
tonsillitis but no skin purpura and no arthritic pain.  His 
familial history was as follows.  His paternal aunt had 
end-stage renal disease and was on dialysis.  His pater-
nal grandfather had died of lung cancer.  His maternal 
uncle had died of esophageal cancer.  He did had no leg 
edema,  skin purpura,  or tonsil enlargement according 
to a physical examination.  His body temperature was 
36.5 °C and his blood pressure was 102/66 mmHg.  His 
consciousness was clear and he had no symptoms sug-
gestive of neurological,  respiratory,  or abdominal 
involvement.  Laboratory findings are summarized in 
Table 1.  The serum levels of Cr,  IgA,  IgG,  IgM,  com-
plement (C) 3 and C4,  and total hemolytic complement 
(CH50) were within the normal ranges.  Urinalysis 
showed that he did not have proteinuria (qualitative test 
negative,  0.09 g/gCr) but did have hematuria (sediment 
containing 103.4 red blood cells (RBCs) per high power 
field).  Computed tomography (CT) showed no abnor-
malities in the urogenital tracts.  Thus,  we made a pos-
sible clinical diagnosis of chronic glomerulonephritis.  
To obtain a histopathological diagnosis,  we performed 
percutaneous renal biopsy.  The histological findings 
were as follows.  Light microscopy identified a slight 
tubulointerstitial disorder (atrophied and fibrotic area 
was < 5% of the whole area) and 29 glomeruli with 1 
small fibro-cellular crescent (Fig. 1A and B) and 1 adhe-
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Fig. 1　 Findings of renal biopsy.  (A and 
B) Light microscopy showing a small ﬁbro-
cellular crescent in PAS stain (A) and in 
PAM stain (B).  (C) Immunoﬂuorescence 
showing a strong and granular deposition of 
IgA (3+ ) in the mesangial area.  (D) 
Electron microscopy exhibiting numerous 
electron-dense deposits in the mesangium.  
White asterisk denotes a large hemispheri-
cal deposit characteristic of IgA nephropa-
thy.  PAS,  Periodic acid－Schiﬀ; PAM,  
Periodic acid－methenamine－silver; Ig,  
immunoglobulin.
sion.  Immunofluorescent examination revealed a 
strong IgA granular deposition (3 + ) in the mesangial 
area (Fig. 1C),  along with mesangial staining for IgG 
(1 + ) and C3 (1 + ).  Furthermore,  electron microscopy 
demonstrated numerous electron-dense deposits in the 
mesangial area (Fig. 1D).  On the basis of these findings,  
the diagnosis of IgA nephropathy was confirmed.  
Therefore,  we performed tonsillectomy and steroid 
pulse therapy to achieve complete clinical remission.  
He underwent tonsillectomy 7 months after the diagno-
sis.  Four months after the tonsillectomy,  he received 
steroid pulse therapy (high-dose methylprednisolone 
(0.5 g/day for 3 days for three courses) followed by oral 
prednisolone at an initial dose of 30 mg/day on alter-
nate days).  Sixteen days after the steroid pulse therapy,  
he had no hematuria.  After being discharged from our 
hospital,  he received oral prednisolone treatment with 
a gradual decrease in dosage over 1 year at his local 
doctor’s office.  He is on a good course.  From the view-
point of therapeutic diagnosis,  we considered that he 
actually developed IgAN,  and that tonsillectomy and 
steroid pulse therapy were well tolerated without any 
major adverse events.
Discussion
We experienced a case of XLT who was diagnosed 
with IgAN by renal biopsy.  The patient received tonsil-
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Table 1　 Laboratory data
Peripheral blood Serological test Coagulation－ﬁbrinolysis system
　WBC (/µl) 4370 　CRP (mg/dl) 0.07 　PT (second) 11.5
　RBC (×104/µl) 464 　CH50 (U/ml) 45 　PT (%) 98
　Hb (g/dl) 13.6 　C3 (mg/dl) 90.0 　PT-INR 1.01
　Plt (×104/µl) 12.7 　C4 (mg/dl) 25.2 　APTT (second) 30.0
　MPV (ﬂ) 8.5 　IgG (mg/dl) 1154.9 　Fibrinogen (mg/dl) 30.4
Blood chemistry 　IgA (mg/dl) 260.6 　FDP (µg/ml) 3.0
　TP (g/dl) 6.8 　IgM (mg/dl) 28.5 　D-dimer (µg/ml) 0.9
　Alb (g/dl) 4.2 　IgA/C3 ratio 2.90 Urinalysis
　AST (IU/l) 15 　Rheumatoid factor (IU/ml) 1.5 　pH 7.5
　ALT (IU/l) 10 　ANA 0.12 　Urine protein (± )
　LDH (IU/l) 150 　PR3-ANCA (IU/ml) <0.50 　UTP/Cr (g/gCr) 0.09
　BUN (mg/dl) 9.4 　MPO-ANCA (IU/ml) <0.50 　Occult blood (2+ )
　Cr (mg/dl) 0.73 　Anti-GBM antibody (U/ml) <1.40 　Sediment RBC (/HPF) 103.4
　UA (mg/dl) 4.5 Tumor marker 　Sediment WBC (/HPF) 0.3
　Na (mmol/l) 140 　CEA (ng/ml) 0.42 　U-NAG (U/L) 6.0
　K (mmol/l) 3.8 　CA19-9 (U/ml) 3.8 U-β2MG (mg/l) 0.20
　Cl (mmol/l) 105 Serum immunoelectrophoresis Urine immunoelectrophoresis
　Ca (mmol/l) 8.9 　Monoclonal protein (－) 　BJP (－)
　P (mmol/l) 3.1 　Monoclonal protein (－)
WBC,  white blood cell value; RBC,  red blood cell; Hb,  hemoglobin value; Plt,  platelet value; MPV,  mean platelet volume; TP,  serum 
total protein value; Alb,  serum albumin value; AST,  serum aspartate aminotransferase value; ALT,  serum aspartate aminotransferase 
value; ɤGTP,  serum ɤ-glutamyltransferase value; LDH,  serum lactate dehydrogenase value; BUN,  blood urea nitrogen level; Cr,  serum 
creatinine level; UA,  serum ureic acid concentration; Na,  serum sodium concentration; K,  serum potassium concentration; CL,  serum 
chloride concentration; Ca,  serum calcium concentration; P,  serum phosphate concentration; CRP,  serum C-reactive protein level;  
CH50,  serum total hemolytic complement level; C3,  serum complement C3 level; C4,  serum complement C4 level; IgG,  serum immuno-
globulin G level; IgA,  serum immunoglobulin level; IgM,  serum immunoglobulin M level; ANA,  serum antinuclear antibody level; PR3-
ANCA,  proteinase-3-antineutrophil cytoplasmic antibody; MPO-ANCA,  myeloperoxidase-antineutrophil cytoplasmic antibody; GBM,  glo-
merular basement membrane; CEA,  serum carcinoembryonic antigen level; CA19-9,  serum carbohydrate antigen 19-9l evel; PT,  
prothrombin time; PT－INR,  prothrombin time － international normalized ratio; APTT,  activated partial thromboplastin time; FDP,  ﬁbrin 
degradation products; HPF,  high-power ﬁeld; UTP/Cr,  urine total protein to creatinine ratio; U-NAG,  urine N-acetyl-β-D-glucosaminidase 
level; U-β2MG,  urine β2 microglobulin level; BJP,  Bence Jones proteinuria.
lectomy plus steroid pulse therapy and has maintained 
remission after the treatment.
His histological abnormality obtained by renal 
biopsy was mild.  However,  an occasionally reported 
complication associated with XLT is IgA nephropathy 
leading to chronic renal failure.  Actually,  he had 
anamnestic history of macrohematuria after tonsillitis.  
In consideration of his youth,  he should have a very 
long time to live.  If his tonsillitis relapses repeatedly,  it 
could aggravate the symptoms of IgAN for the rest of his 
life.  Kawaguchi et al.  [17] reported that steroid pulse 
therapy combined with tonsillectomy significantly 
increased the probability of clinical remission,  which 
was defined as negative proteinuria by dipstick testing 
and urinary erythrocytes of less than 1/high-power field 
in IgAN patients with glomerular hematuria and mini-
mal proteinuria; those authors found that this combi-
nation of therapies was more effective in patients with 
less-severe histological findings.  Our patient showed 
marked hematuria (sediment RBC 103.4/HPF).  We 
anticipated that steroid pulse therapy combined with 
tonsillectomy could allow our patient to achieve that 
definition of clinical remission,  and indeed this 
approach resulted in complete clinical remission.
IgAN is recognized as the most common glomerular 
disease in Asia and some countries in Europe [18-20].  
The clinical manifestations vary; microscopic hematu-
ria and proteinuria are the most common ones.  
However,  approximately 15% to 20% of affected 
patients progress to end-stage renal disease (ESRD) 
within 10 years,  and 40% within 20 years [21].  There 
are several therapeutic options,  such as immunosup-
pressive treatment and blood pressure control with a 
renin−angiotensin system [22].  In Japan,  tonsillec-
tomy combined with steroid pulse therapy has been 
demonstrated to have a good clinical outcome in 
patients with IgAN [23].  Currently histopathological 
analysis of renal biopsies is considered the gold stan-
dard for diagnosis and contributes to both the making 
of therapeutic strategy and the prediction of prognosis 
[24].  The histopathological hallmark of IgAN is the 
predominance of deposition with immune complex 
containing IgA in mesangial regions,  but its pathoge-
netic factors remain obscure.   Previous studies have 
revealed that aberrantly glycosylated IgA1 plays an 
important role in the pathogenesis of IgAN [25-28],  
e.g.,  the hinge-region O-linked glycans are galac-
tose-deficient [29].  Yasutake et al.  [30] reported that the 
serum level of galactose-deficient IgA1 (Gd-IgA1) 
tended to be higher in IgAN patients than in patients 
with other renal or nonrenal diseases.  We have mea-
sured the serum levels of Gd-IgA1 in patients with 
IgAN,  which ranged from 1.5 to 21.4 µg/mL (n = 20,  
average value,  5.9 ± 4.9 µg/mL),  and found the results 
comparable to those reported.  In the present case,  no 
marked increase in the serum level of Gd-IgA1 was seen 
(3.2 µg/mL).
XLT is a congenital disorder characterized in general 
by thrombocytopenia and small platelets,  without any 
other complications of WAS.  The pathogenesis is a mild 
allelic variant caused by mutations in the WASP gene 
[31].  Since patients with XLT rarely have serious 
immune disorders compared with WAS patients,  they 
tend to have better prognoses than WAS patients.  
Actually,  XLT patients show excellent long-term sur-
vival compared to WAS patients [32].  On the other 
hand,  XLT patients do not always experience event-free 
survival [32].  The occasionally reported complications 
associated with XLT are severe bleeding,  cancer,  and 
IgA nephropathy leading to chronic renal failure [31].  
There are several case reports of WAS/XLT associated 
with nephropathy,  but few patients receive a renal 
biopsy due to the bleeding tendency in WAS/XLT 
(Table 2) [15 , 33-42].  More patients with WAS/XLT are 
male than female,  but this might be because WAS/XLT 
occurs more often in men.  Our patient was close to the 
mean age for the onset of nephropathy in WAS/XLT,  as 
seen in Table 2.  Therefore,  we consider that our patient 
developed IgA nephropathy associated with XLT.
In their experimental model,  Shimizu et al.  [43] 
revealed that serum IgA and IgA production by splenic 
B cells increased in WASp-deficient mice compared to 
wild-type mice.  The levels of sialylation and galacto-
sylation of N-glycans in serum IgA in Was-KO mice 
were significantly reduced.  This indicated that the pro-
duction of aberrant IgA production increased in WASp-
deficient mice.  In a clinical setting,  Hoshino et al.  [40] 
reported that IgAN patients with XLT were clinically 
and histologically improved after bone marrow trans-
plantation (BMT),  indicating that the increased IgA 
production and aberrant glycosylation of IgA may be 
critically involved in the pathogenesis of glomerulone-
phritis in WAS/XLT.  At present,  several hypotheses 
have been proposed to explain the relationship between 
IgA nephropathy and WAS/XLT.  As described previ-
ously [43],  the production of aberrant IgA increases in 
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WAS/XLT; that is,  the immunodeficiency due to aber-
rant CD43 also increases susceptibility to infection,  
leading to increased IgA production [44].  Furthermore,  
because a deficient reticuloendothelial system cannot 
adequately remove IgA,  IgA nephropathy is easily 
induced by recurrent infections and the infection-re-
lated formation of IgA immune complexes [36].  
Because the aforementioned mechanisms are related to 
each other,  patients with WAS/XLT might often 
develop IgA nephropathy.  However,  serum levels of 
Gd-IgA1 were not markedly increased in our patient.  
In addition,  his histological abnormality obtained by 
renal biopsy was mild and the clinical symptom of IgAN 
was minor.  Berthoux et al.  [45] reported that the serum 
levels of IgA and Gd-IgA1 were positively associated 
with the progression of IgAN.  Furthermore,  the phe-
notypic level of XLT in our patient was not so severe.  
Actually,  he had low-grade thrombocytopenia and no 
small platelets.  In fact,  certain proportions of patients 
with IgAN have non-increased serum levels of both IgA 
and Gd-IgA1.  Further studies are required to investi-
gate the serum levels of IgA and Gd-IgA1 as accurate 
surrogate markers of IgAN.
This is the first case of XLT complicated with mild 
IgAN that was treated with tonsillectomy combined 
with steroid pulse therapy.  The treatment resulted in a 
good renal prognosis.  Biopsy-proven kidney diseases,  
mainly IgAN,  associated with WAS reportedly have 
very poor outcomes.  Therefore,  such patients have 
received aggressive treatments including kidney trans-
plantation,  splenectomy,  and BMT.  On the other hand,  
there are few reported cases of IgAN complicated with 
XLT,  and the treatment has been inconsistent.  
Matsukura [38] reported 2 patients with IgAN associ-
ated with XLT.  One of those patients was treated with 
low-dose oral prednisolone and angiotensin-converting 
enzyme inhibitor,  but achieved only partial remission-
The other patient developed ESRD requiring hemodial-
ysis.  Tonsillectomy combined with subsequent steroid 
pulse therapy may be a therapeutic strategy for mild 
IgAN with XLT.  To evaluate its long-term prognosis,  
we will need a longer observation period and a larger 
number of patients.
In conclusion,  we report a case of IgAN compli-
cated with XLT that was successfully treated with ton-
sillectomy and steroid pulse therapy.  This combined 
therapy may be worth considering in patients with a 
mild form of IgAN with XLT.  We should be careful 
when dealing with patients with WAS/XLT,  because 
they may develop IgA nephropathy,  which this therapy 
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Table 2　Clinical and pathologic ﬁndings of nephropathy associated with WAS/XLT
Patient Age Gender Clinical diagnosis Serum IgA level Pathologic ﬁndings Reference No.
No. (mg/dl)
1 2 Male WAS Not described Interstitial nephritis 15
2 4 Male WAS Not described Chronic proliferative GN with focal crescent formation 15
3 12 Female WAS variant Elevated Immune-complex GN IF: IgA and IgM, C3 33
4 46 Male WAS Elevated MPGN with crescent and mesangial IgA deposit 34
5 33 Male WAS Elevated MPGN IF: negative for IgA 35
6 12 Male WAS Elevated MPGN IF: IgA 36
7 35 Female WAS carrier Normal Diﬀuse proliferative GN with cellular crescent  
IF: IgA,  ﬁbrinogen,  C3
37
8 8 Male XLT Elevated IgAN　　　IF: IgA,  C3 38
9 35 Male XLT Normal IgAN　　　IF: IgA,  C3 38
10 8 Male WAS Elevated IgAN with FSGS and focal ATIN IF: IgA,  C3 39
11 8 Male XLT Normal IgAN　　　IF: IgA,  IgG 40
12 21 Male WAS Elevated IgAN 41
13 8 Male XLT Not described IgAN 42
14 16 Male XLT Normal IgAN　　　IF: IgA,  C3 Present case
WAS,  Wiskott‒Aldrich syndrome; XLT,  x-linked thrombocytopenia; IgAN,  IgA nephropathy; C3,  complement3; GN,  glomerulonephritis;  
IF,  immunoﬂuorescence; MPGN,  membranoproliferative glomerulonephritis; FSGS,  focal segmental glomerular sclerosis; ATIN,  acute 
tubulointerstitial nephriti.
can treat.
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